title: Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment.
abstract: An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients' adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.
authors.affiliation: Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon ; Approved Centre for HIV Treatment and Pneumology Service, Yaounde Jamot Hospital, Cameroon.
authors.forename: Eric W Pefura
authors.initials: EW
authors.lastname: Yone
authors.forename: André P
authors.initials: AP
authors.lastname: Kengne